农业百科

Researchers at Amorepacific have identified a microbiome-derived culture extract that may address post-acne hyperpigmentation by targeting new melanin production and pigment already accumulated in the skin.

Why it matters: T-cell engagers have been highly effective in multiple myeloma but hard to tolerate, and GSK is buying a design meant to fix that. By binding T cells while targeting two validated tumor-associated antigens at once, the Chimagen molecule is intended to produce deeper and more durable responses than existing engagers with a better safety profile, which GSK says could open the class to broader adoption and earlier lines of treatment for the third most-common blood cancer globally. The prize it cites is a U.S. myeloma T-cell-engager market that external forecasts put above $10 billion by 2032.

Why it matters: TGF-β signaling is an important driver of fibrosis and an attractive target in IPF. AGMB-447 blocks ALK5, a receptor that transmits TGF-β signals into cells, but the inhibition of this pathway throughout the body has been held back by safety concerns.

Why it matters: Initial feedback from EMA’s Committee for Medicinal Products for Human Use (CHMP) suggests the biotech’s attempt to get the agency to overturn its original decision has failed. Confirmation of CHMP’s continued resistance to approval would intensify pressures on cash-strapped MaaT. 

Why it matters: ALS remains notoriously difficult to treat, and the SEALS study did not establish an effect on its prespecified biomarkers. The more encouraging clinical findings come from post-hoc analyses, making them signals that will need confirmation in a larger trial.

Why it matters: The move is a dramatic reset for one of Europe’s pioneers of off-the-shelf CAR-T. As recently as January, Cellectis described itself as a late-stage allogeneic CAR-T company and expected pivotal Phase 2 data from its lead program this year. It will now replace clinical-stage oncology assets with two programs that have yet to enter human testing.

Why it matters: Focused on ACLF, Genfit has built a pipeline led by the G1090N, which delivered Phase 1 data in January, and featuring multiple preclinical programs. The pipeline positions Genfit to treat various aspects of ACLF but, with the biotech ending a Phase 2 program last year over a safety signal, all the drug candidates are in early development.

A produção brasileira de grãos na safra 2026/27 pode chegar a 366,6 milhões de toneladas. O resultado positivo projetado…

Foto: Breno Lobato O trigo ocupa posição estratégica na agricultura brasileira, tanto pela importância econômica quanto …